Good News on Thyroid Cancer War (OXGN)
OXiGENE, Inc. (NASDAQ: OXGN) is surging on news that it showed positive results from a randomized, controlled, Phase II/III study of ZYBRESTAT at the 14th International Thyroid Congress in Paris for its Anaplastic Thyroid Cancer treatment.
The results were presented by Rossella Elisei, M.D., of the University of Pisa. In this 80-patient study, the median overall survival time was 5.1 months for patients who received ZYBRESTAT and chemotherapy when compared with a median survival time of 4.1 months for patients receiving chemotherapy alone (Hazard Ratio 0.71). This represents a 29% reduction in the risk of dying for patients receiving ZYBRESTAT and chemotherapy.
Of patients treated with ZYBRESTAT and chemotherapy, 48% were alive at six months, compared with 37% percent of patients treated with the control arm regimen.
More importantly, at one year, 23% of patients treated with ZYBRESTAT and chemotherapy were alive compared to 9% of patients treated with chemotherapy alone.
The most common side effects reported with ZYBRESTAT and chemotherapy were neutropenia, transient hypertension and tumor pain.
JON C. OGG
Comments
Leave a Reply
